gptkbp:instance_of
|
gptkb:drug
|
gptkbp:activities
|
inhibits RNA polymerase
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
gptkbp:brand
|
Dificid
|
gptkbp:clinical_trial
|
Phase III trials
|
gptkbp:contraindication
|
hypersensitivity to fidaxomicin
|
gptkbp:developed_by
|
Optimer Pharmaceuticals
|
gptkbp:discovered_by
|
2000s
|
gptkbp:dissolved
|
soluble in water
|
gptkbp:duration
|
10 days
|
gptkbp:formulation
|
tablets
|
https://www.w3.org/2000/01/rdf-schema#label
|
fidaxomicin
|
gptkbp:ingredients
|
C27 H27 N3 O9 S
|
gptkbp:is_atype_of
|
J01 X X13
|
gptkbp:is_effective_against
|
high effectiveness against C. difficile
|
gptkbp:is_used_for
|
gptkb:Clostridium_difficile_infection
|
gptkbp:lifespan
|
12 hours
|
gptkbp:manager
|
oral
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
gptkbp:price
|
expensive
|
gptkbp:rounds
|
feces
|
gptkbp:side_effect
|
nausea
abdominal pain
vomiting
diarrhea
|
gptkbp:storage
|
room temperature
|
gptkbp:targets
|
Gram-positive bacteria
|
gptkbp:type_of
|
74711-36-7
|
gptkbp:water_resistance
|
low resistance rates
|
gptkbp:bfsParent
|
gptkb:Clostridium_difficile
|
gptkbp:bfsLayer
|
5
|